FBIO — Fortress Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Fortress Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-103	-165	-214	-154	-121
Depreciation
Amortisation
Non-Cash Items	20.4	6.81	27.8	32.5	44.3
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-4.78	36.4	-0.715	-12.5	-8.13
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	-83.7	-117	-179	-128	-80.2
Capital Expenditures	-3.13	-4.97	-2.71	-5.06	-15
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-4.04	45.5	-20.2	2.96	0
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-7.16	40.5	-22.9	-2.1	-15
Financing Cash Flow Items	41.5	119	14.2	4.59	12.3
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	172	149	75.3	32.7	70.6
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	81.6	73	-127	-97.6	-24.6